Methods Of Treating Skin Cancer With Carboxypeptidase Vitellogenic Like (CPVL) Inhibitors

A method of treating a subject with a therapeutic agent that treats or inhibits skin cancer wherein the subject has skin cancer, or preventing a subject from developing skin cancer by administering a therapeutic agent that prevents skin cancer, the method comprising the steps of:

• determining whether the subject has a Carboxypeptidase Vitellogenic Like (CPVL) missense variant nucleic acid molecule encoding a CPVL predicted loss-of-function polypeptide by:
• obtaining or having obtained a biological sample from the subject;
• and
• performing or having performed a sequence analysis on the biological sample to determine if the subject has a genotype comprising the CPVL missense variant nucleic acid molecule;
• and
• administering or continuing to administer the therapeutic agent that treats, prevents, or inhibits skin cancer in a standard dosage amount to a subject that is CPVL reference, and/or administering a CPVL inhibitor to the subject;
• administering or continuing to administer the therapeutic agent that treats, prevents, or inhibits skin cancer in an amount that is the same as or less than a standard dosage amount to a subject that is heterozygous for the CPVL missense variant nucleic acid molecule, and/or administering a CPVL inhibitor to the subject;
• or
• administering or continuing to administer the therapeutic agent that treats, prevents, or inhibits skin cancer in an amount that is the same as or less than a standard dosage amount to a subject that is homozygous for the CPVL missense variant nucleic acid molecule;
• wherein the presence of a genotype having the CPVL missense variant nucleic acid molecule encoding the CPVL predicted loss-of-function polypeptide indicates the subject has a decreased risk of developing skin cancer.